<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H8780E04E833547B4AB72C4008CA99A9C" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5355 IH: Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-15</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5355</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250915">September 15, 2025</action-date><action-desc><sponsor name-id="C001059">Mr. Costa</sponsor> (for himself and <cosponsor name-id="V000134">Ms. Van Duyne</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To direct the Secretary of Health and Human Services to carry out activities to promote screenings for liver diseases in newborns, and for other purposes.</official-title></form><legis-body id="H9AFC3CB3CC454E99BD834515D89FE164" style="OLC"> 
<section id="HDBD453AEC60C40429406903FC05C1F1D" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act</short-title></quote>.</text></section> <section id="H8626E419840C4B069A8EAAC68BE03766"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds that—</text> 
<paragraph id="H1F083AAEB29C4738A679FA254841A28F"><enum>(1)</enum><text display-inline="yes-display-inline">the life of California teenager Ian Kalvinskas—who received a liver transplant, fulfilled his goal of interning on Capitol Hill, and died from cancer on June 27, 2025—demonstrates the urgent need for earlier detection of pediatric liver disease, lifelong follow-up, and wider access to donor organs;</text></paragraph> <paragraph id="H390391BACFB245EB97FC6111C533F372"><enum>(2)</enum><text display-inline="yes-display-inline">pediatric primary liver tumors are among the fastest-rising childhood cancers in the United States, with hepatoblastoma increasing by approximately 2 percent per year to and now approaching 1.7 cases per million children; although the overall 5-year relative survival rate from a pediatric primary liver tumor is about 77 percent, survival falls below 60 percent for adolescents and for tumors diagnosed with distant metastases;</text></paragraph> 
<paragraph id="H438104EFF64D461483A25083B08504F5"><enum>(3)</enum><text>biliary atresia, a neonatal malformation of the bile ducts occurring in roughly 1 in 12,000 live births and the leading indication for infant liver transplantation, shows transplant-free survival that roughly doubles when a Kasai portoenterostomy is performed before 60 days of life;</text></paragraph> <paragraph id="H58E8B984FCDE49069B0C3CAE384E2DAF"><enum>(4)</enum><text>clinically validated early-warning tools can detect cholestatic liver disease in time for therapeutic intervention, including—</text> 
<subparagraph id="H45F7C65806F546B7B95EDF13559C15ED"><enum>(A)</enum><text>routine direct-bilirubin measurement in the newborn heel-stick panel, which when used in multi-center, United States pilots detected 100 percent of biliary-atresia cases with minimal false positives; and</text></subparagraph> <subparagraph id="H279A1E1AA3C148AEAFA2551CD5E34CCD"><enum>(B)</enum><text>improved education of pediatric primary care providers to be alert to early warning signs of biliary atresia with expedited referral to pediatric liver specialists;</text></subparagraph></paragraph> 
<paragraph id="H9FB1E52BED8D4B8A9F31D06508ECDA30"><enum>(5)</enum><text>despite recent liver donor allocation reforms, more than 1 in 10 infants and more than 1 in 20 older children on the United States liver-transplant wait list die before receiving a graft;</text></paragraph> <paragraph id="H8C7B7FC09A684C61B8FD06B6A1258F21"><enum>(6)</enum><text>living-donor liver transplantation expands the pediatric organ pool and delivers equivalent or superior 1-year, 3-year, and 5-year graft and patient survival compared with deceased-donor grafts; and</text></paragraph> 
<paragraph id="H537F7EAABCEE49A4A9782478C4D9BD07"><enum>(7)</enum><text>many children with rare liver diseases, including liver cancer, are only able to receive timely transplants through physician advocacy to petition for exceptions to the standard listing practices.</text> </paragraph></section> <section id="H06B8F96F604E434684F270634DA68374"><enum>3.</enum><header>Pediatric liver disease outcomes and newborn screening panels</header> <subsection id="H70F6987940204DF2BED54EB252AE92FC"><enum>(a)</enum><header>GAO Study</header><text display-inline="yes-display-inline">The Comptroller General of the United States shall conduct a study on—</text> 
<paragraph id="H3C8FDBB486B443C4B766B19E79B17759"><enum>(1)</enum><text display-inline="yes-display-inline">federally funded initiatives to improve early detection and treatment of pediatric liver tumors, including education programs for healthcare providers, as well as research to identify risk factors and innovative therapeutic strategies;</text></paragraph> <paragraph id="H08DC33C636CE4F289DB5944EB88C801E"><enum>(2)</enum><text>to the extent reliable data are available, what is known about trends in pediatric liver-transplant wait-list mortality, including a breakdown by geography, race, insurance status, diagnosis, and severity of illness; and</text></paragraph> 
<paragraph id="H6F07636B55F24C44B49C101EC3CBC4BF"><enum>(3)</enum><text>to the extent reliable data are available, what is known about the cost effectiveness of adding direct-bilirubin as a screening test for biliary atresia and other cholestatic liver diseases to State newborn-screening panels.</text></paragraph> </subsection> <subsection id="HF468A06F6C7542219FEC864BA399B4D4"><enum>(b)</enum><header>Report to Congress</header><text>Not later than one year after the date of enactment of this Act, the Comptroller General shall transmit to Congress a report on the results of the study.</text></subsection></section> 
<section id="H54606D96F08A4244A2072086EA66E90B"><enum>4.</enum><header>Public education program</header> 
<subsection id="HC007A71D222841EDB038F32D0D5EA064"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services, acting through the Administrator for the Health Resources and Services Administration, in consultation with the Director of the Centers for Disease Control and Prevention (in this section referred to as the <quote>CDC</quote>), shall carry out a public education program under which the Secretary shall develop and disseminate plain-language materials on—</text> <paragraph id="HE769EBEA675F499AB51DF12393B5F5A4"><enum>(1)</enum><text>early signs of pediatric liver disease; and</text></paragraph> 
<paragraph id="H6D9E46C487354F73A93F07CF03F6A55C"><enum>(2)</enum><text>the option and safety of living liver donation.</text></paragraph></subsection> <subsection id="HF00B6F72D95A404AB70B8CE4F4E42EDF"><enum>(b)</enum><header>Implementation</header><text display-inline="yes-display-inline">In carrying out the program under subsection (a), the Secretary may—</text> 
<paragraph id="H55BC7A12B7B4473A9ECDD9DB67AE9A5C"><enum>(1)</enum><text>coordinate implementation of the program with programs of the CDC, including the National Comprehensive Cancer Control Program (or any successor campaign); and</text></paragraph> <paragraph id="HEC7A567D82674A2189E9DB762DDA1250"><enum>(2)</enum><text>in addition to the program referred to in paragraph (1), disseminate materials developed under this section through any other public-education initiative of the Department of Health and Human Services that promotes liver-disease prevention, pediatric cancer awareness, or living-organ donation.</text></paragraph></subsection> 
<subsection id="H435056FCA22B47A1B53DAEB0BC0256EA"><enum>(c)</enum><header>GAO report to Congress</header><text display-inline="yes-display-inline">Not later than 3 years after the date on which the Secretary initiates the program under subsection (a), the Comptroller General of the United States shall transmit to Congress a report on the results of the program.</text></subsection> <subsection id="H5736FBC0E3414B12A39472D13D7C472A"><enum>(d)</enum><header>Funding</header><text display-inline="yes-display-inline">No additional funds are authorized to be appropriated for the purpose of carrying out this section.</text></subsection> </section> 
</legis-body></bill>

